ACTR1A
geneOn this page
Also known as ARP1Arp1A
Summary
ACTR1A (actin related protein 1A, HGNC:167) is a protein-coding gene on chromosome 10q24.32, encoding Alpha-centractin (P61163). Part of the ACTR1A/ACTB filament around which the dynactin complex is built. It is a selective cancer dependency (DepMap: 78.1% of cell lines).
This gene encodes a 42.6 kD subunit of dynactin, a macromolecular complex consisting of 10-11 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein. It is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit is present in 8-13 copies per dynactin molecule, and is the most abundant molecule in the dynactin complex. It is an actin-related protein, and is approximately 60% identical at the amino acid level to conventional actin.
Source: NCBI Gene 10121 — RefSeq curated summary.
At a glance
- GWAS associations: 13
- Clinical variants (ClinVar): 39 total — 2 pathogenic
- Cancer dependency (DepMap): dependent in 78.1% of screened cell lines
- MANE Select transcript:
NM_005736
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:167 |
| Approved symbol | ACTR1A |
| Name | actin related protein 1A |
| Location | 10q24.32 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ARP1, Arp1A |
| Ensembl gene | ENSG00000138107 |
| Ensembl biotype | protein_coding |
| OMIM | 605143 |
| Entrez | 10121 |
Gene structure
Transcript identifiers
Ensembl transcripts: 19 — 14 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay
ENST00000369905, ENST00000470322, ENST00000480947, ENST00000481044, ENST00000487599, ENST00000494549, ENST00000636707, ENST00000900299, ENST00000900300, ENST00000900301, ENST00000900302, ENST00000900303, ENST00000900304, ENST00000900305, ENST00000900306, ENST00000900307, ENST00000972051, ENST00000972052, ENST00000972053
RefSeq mRNA: 1 — MANE Select: NM_005736
NM_005736
CCDS: CCDS7536
Canonical transcript exons
ENST00000369905 — 11 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001613806 | 102502600 | 102502712 |
| ENSE00001861057 | 102479229 | 102480965 |
| ENSE00003250773 | 102482001 | 102482175 |
| ENSE00003466738 | 102481837 | 102481898 |
| ENSE00003542714 | 102490549 | 102490613 |
| ENSE00003583063 | 102488150 | 102488275 |
| ENSE00003637760 | 102489063 | 102489138 |
| ENSE00003643387 | 102483011 | 102483103 |
| ENSE00003644632 | 102484160 | 102484376 |
| ENSE00003668590 | 102481132 | 102481172 |
| ENSE00003685737 | 102485609 | 102485733 |
Expression profiles
Bgee: expression breadth ubiquitous, 291 present calls, max score 98.65.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 106.0542 / max 540.4059, expressed in 1827 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 111179 | 97.5285 | 1827 |
| 111178 | 7.9999 | 1742 |
| 111177 | 0.5259 | 272 |
Top tissues by expression
293 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cortical plate | UBERON:0005343 | 98.65 | gold quality |
| ganglionic eminence | UBERON:0004023 | 98.10 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 97.61 | gold quality |
| lower esophagus | UBERON:0013473 | 97.60 | gold quality |
| gastrocnemius | UBERON:0001388 | 97.44 | gold quality |
| prefrontal cortex | UBERON:0000451 | 97.34 | gold quality |
| right frontal lobe | UBERON:0002810 | 97.29 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 97.24 | gold quality |
| muscle of leg | UBERON:0001383 | 97.14 | gold quality |
| stromal cell of endometrium | CL:0002255 | 97.03 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 97.02 | gold quality |
| cingulate cortex | UBERON:0003027 | 96.83 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 96.83 | gold quality |
| apex of heart | UBERON:0002098 | 96.81 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 96.79 | gold quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 96.72 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 96.70 | gold quality |
| popliteal artery | UBERON:0002250 | 96.60 | gold quality |
| tibial artery | UBERON:0007610 | 96.59 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 96.58 | gold quality |
| mucosa of stomach | UBERON:0001199 | 96.50 | gold quality |
| right coronary artery | UBERON:0001625 | 96.48 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 96.44 | gold quality |
| left coronary artery | UBERON:0001626 | 96.42 | gold quality |
| aorta | UBERON:0000947 | 96.39 | gold quality |
| esophagus | UBERON:0001043 | 96.39 | gold quality |
| right atrium auricular region | UBERON:0006631 | 96.30 | gold quality |
| islet of Langerhans | UBERON:0000006 | 96.29 | gold quality |
| thoracic aorta | UBERON:0001515 | 96.22 | gold quality |
| ascending aorta | UBERON:0001496 | 96.20 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 9.83 |
| E-MTAB-7606 | no | 744.34 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
140 targeting ACTR1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4673 | 100.00 | 66.64 | 1490 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-6758-5P | 100.00 | 66.21 | 1470 |
| HSA-MIR-6856-5P | 100.00 | 65.47 | 1298 |
| HSA-MIR-3925-3P | 100.00 | 69.95 | 1237 |
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-6870-5P | 99.99 | 68.55 | 2115 |
| HSA-MIR-4645-5P | 99.98 | 65.81 | 1284 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-4723-5P | 99.97 | 68.70 | 2034 |
| HSA-MIR-5698 | 99.97 | 68.49 | 2029 |
| HSA-MIR-7111-5P | 99.97 | 68.48 | 2062 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-767-5P | 99.95 | 70.85 | 993 |
| HSA-MIR-6845-3P | 99.94 | 66.88 | 1439 |
| HSA-MIR-497-5P | 99.92 | 71.83 | 2674 |
| HSA-MIR-15A-5P | 99.90 | 72.80 | 2787 |
| HSA-MIR-15B-5P | 99.90 | 72.78 | 2798 |
| HSA-MIR-16-5P | 99.90 | 72.80 | 2780 |
| HSA-MIR-195-5P | 99.90 | 72.81 | 2805 |
| HSA-MIR-106A-5P | 99.90 | 73.94 | 2683 |
| HSA-MIR-95-5P | 99.89 | 72.17 | 3973 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 78.1% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 3)
- ARP1 interacted with two regions of the FVII 5’ flanking region, the hepatic nuclear factor 4 binding region and the nuclear hormone response region, indicating a role for ARP1 in transcriptional modulation of the FVII gene. (PMID:12871323)
- point mutation observed by transcriptome sequencing of malignant pleural mesothelioma tumors (PMID:18303113)
- An important role for ACTR1A in induction of pro-inflammatory cytokines.TLR2 interacts with alpha-centractin. (PMID:31221720)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | actr1b | ENSDARG00000011611 |
| mus_musculus | Actr1a | ENSMUSG00000025228 |
| rattus_norvegicus | Actr1a | ENSRNOG00000019725 |
| drosophila_melanogaster | Arp1 | FBGN0011745 |
| caenorhabditis_elegans | WBGENE00013168 |
Paralogs (26): ACTR6 (ENSG00000075089), ACTB (ENSG00000075624), ACTL6B (ENSG00000077080), ACTR5 (ENSG00000101442), ACTR3C (ENSG00000106526), ACTA2 (ENSG00000107796), ACTR8 (ENSG00000113812), ACTR1B (ENSG00000115073), ACTR3 (ENSG00000115091), ACTL8 (ENSG00000117148), ACTRT1 (ENSG00000123165), ACTR10 (ENSG00000131966), ACTR3B (ENSG00000133627), ACTL6A (ENSG00000136518), ACTR2 (ENSG00000138071), ACTA1 (ENSG00000143632), ACTL7B (ENSG00000148156), ACTC1 (ENSG00000159251), ACTG2 (ENSG00000163017), ACTBL2 (ENSG00000169067), ACTRT2 (ENSG00000169717), ACTL9 (ENSG00000181786), ACTG1 (ENSG00000184009), ACTRT3 (ENSG00000184378), ACTL7A (ENSG00000187003), ACTL10 (ENSG00000288649)
Protein
Protein identifiers
Alpha-centractin — P61163 (reviewed: P61163)
Alternative names: ARP1, Actin-RPV, Centrosome-associated actin homolog
All UniProt accessions (4): P61163, A0A1B0GVS3, A0A384NQ21, R4GMT0
UniProt curated annotations — full annotation on UniProt →
Function. Part of the ACTR1A/ACTB filament around which the dynactin complex is built. The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules.
Subunit / interactions. Part of the ACTR1A/ACTB filament around which the dynactin complex is built. The filament contains 8 copies of ACTR1A and 1 ACTB. Interacts with dynein and adapters such as BICD2. Interacts with BCCIP (isoform 2/alpha).
Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Cell cortex.
Similarity. Belongs to the actin family. ARP1 subfamily.
RefSeq proteins (1): NP_005727* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR004000 | Actin | Family |
| IPR004001 | Actin_CS | Conserved_site |
| IPR020902 | Actin/actin-like_CS | Conserved_site |
| IPR043129 | ATPase_NBD | Homologous_superfamily |
Pfam: PF00022
UniProt features (2 total): chain 1, modified residue 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 9B85 | ELECTRON MICROSCOPY | 3.47 |
| 9B7J | ELECTRON MICROSCOPY | 3.49 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P61163-F1 | 93.00 | 0.87 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 1
Function
Pathways and Gene Ontology
Reactome pathways
33 pathways
| ID | Pathway |
|---|---|
| R-HSA-2132295 | MHC class II antigen presentation |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition |
| R-HSA-3371497 | HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand |
| R-HSA-380259 | Loss of Nlp from mitotic centrosomes |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes |
| R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centrosome |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes |
| R-HSA-5620912 | Anchoring of the basal body to the plasma membrane |
| R-HSA-6807878 | COPI-mediated anterograde transport |
| R-HSA-6811436 | COPI-independent Golgi-to-ER retrograde traffic |
| R-HSA-8854518 | AURKA Activation by TPX2 |
| R-HSA-1280218 | Adaptive Immune System |
| R-HSA-1640170 | Cell Cycle |
| R-HSA-168256 | Immune System |
| R-HSA-1852241 | Organelle biogenesis and maintenance |
| R-HSA-199977 | ER to Golgi Anterograde Transport |
| R-HSA-199991 | Membrane Trafficking |
| R-HSA-2262752 | Cellular responses to stress |
| R-HSA-380287 | Centrosome maturation |
| R-HSA-392499 | Metabolism of proteins |
| R-HSA-446203 | Asparagine N-linked glycosylation |
| R-HSA-453274 | Mitotic G2-G2/M phases |
| R-HSA-5617833 | Cilium Assembly |
| R-HSA-5653656 | Vesicle-mediated transport |
| R-HSA-597592 | Post-translational protein modification |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic |
| R-HSA-68877 | Mitotic Prometaphase |
| R-HSA-68886 | M Phase |
| R-HSA-69275 | G2/M Transition |
| R-HSA-69278 | Cell Cycle, Mitotic |
MSigDB gene sets: 216 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, TGCGCANK_UNKNOWN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, ACTGCAG_MIR173P, GGGTGGRR_PAX4_03, GOCC_MICROTUBULE_ORGANIZING_CENTER, TTGGGAG_MIR150, NFKB_Q6, EVI1_05, GROSS_HYPOXIA_VIA_ELK3_UP, GATA1_01, GOCC_CENTROSOME
GO Biological Process (1): vesicle-mediated transport (GO:0016192)
GO Molecular Function (3): ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein binding (GO:0005515)
GO Cellular Component (9): cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), dynactin complex (GO:0005869), microtubule associated complex (GO:0005875), cell cortex (GO:0005938), extracellular exosome (GO:0070062), microtubule organizing center (GO:0005815), cytoskeleton (GO:0005856)
Reactome top-level categories
Rollup of top-14 pathways:
| Category | Pathways |
|---|---|
| G2/M Transition | 3 |
| Centrosome maturation | 2 |
| Adaptive Immune System | 1 |
| Cellular responses to stress | 1 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 1 |
| Mitotic Prometaphase | 1 |
| Assembly of the 9+0 primary cilium | 1 |
| ER to Golgi Anterograde Transport | 1 |
| Golgi-to-ER retrograde transport | 1 |
| Immune System | 1 |
| Membrane Trafficking | 1 |
| Transport to the Golgi and subsequent modification | 1 |
| Vesicle-mediated transport | 1 |
| Cellular responses to stimuli | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| cytoplasm | 2 |
| microtubule cytoskeleton | 2 |
| transport | 1 |
| cellular process | 1 |
| adenyl ribonucleotide binding | 1 |
| purine ribonucleoside triphosphate binding | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| centriole | 1 |
| microtubule organizing center | 1 |
| microtubule associated complex | 1 |
| actin cytoskeleton | 1 |
| protein-containing complex | 1 |
| cell periphery | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
0 interactions, top by confidence (×1000):
IntAct
163 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MED4 | MED19 | psi-mi:“MI:2364”(proximity) | 0.900 |
| ACTR1A | DCTN2 | psi-mi:“MI:0914”(association) | 0.790 |
| DCTN1 | DCTN6 | psi-mi:“MI:0914”(association) | 0.780 |
| DCTN2 | DCTN6 | psi-mi:“MI:0914”(association) | 0.730 |
| DCTN2 | DCTN3 | psi-mi:“MI:0914”(association) | 0.730 |
| DYNLL1 | BLTP3B | psi-mi:“MI:0914”(association) | 0.730 |
| CCT2 | TXNDC9 | psi-mi:“MI:0914”(association) | 0.730 |
| CFTR | ESYT2 | psi-mi:“MI:0914”(association) | 0.710 |
| DCTN1 | DCTN3 | psi-mi:“MI:0914”(association) | 0.710 |
| DYNC1I2 | DYNC1LI2 | psi-mi:“MI:0914”(association) | 0.680 |
| MIS18A | DCTN6 | psi-mi:“MI:0914”(association) | 0.640 |
| DYNLL2 | BLTP3B | psi-mi:“MI:0914”(association) | 0.640 |
| CAPZB | CNOT1 | psi-mi:“MI:0914”(association) | 0.640 |
| CAPZA2 | CNOT1 | psi-mi:“MI:0914”(association) | 0.640 |
| DCTN5 | DCTN6 | psi-mi:“MI:0914”(association) | 0.640 |
| PDCL3 | PEX7 | psi-mi:“MI:0914”(association) | 0.640 |
| CCT3 | TXNDC9 | psi-mi:“MI:0914”(association) | 0.640 |
BioGRID (393): ACTR1A (Affinity Capture-MS), ACTR1A (Affinity Capture-RNA), ACTR1A (Affinity Capture-RNA), ACTR1A (Affinity Capture-MS), ACTR1A (Affinity Capture-MS), ACTR1A (Affinity Capture-MS), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation), ACTR1A (Co-fractionation)
ESM2 similar proteins: A2VD93, A2WNB0, A2XMK6, A3ANB5, A4FUX8, A4IFE3, O00937, O94241, O94805, O96019, O96621, P02583, P12715, P20360, P32381, P42023, P42025, P45888, P45889, P45890, P47117, P51775, P53468, P53469, P53489, P53499, P55805, P61162, P61163, P61164, P85515, P86173, Q09443, Q09849, Q2YDD0, Q4R333, Q4R6J2, Q4R6J9, Q54I79, Q5NBI2
Diamond homologs: A2BDB0, A2XLF2, A2XNS1, A3C6D7, A4IFE3, F2Z5G5, O17320, O18840, O65314, O81221, P02578, P04829, P0C539, P0CJ46, P0CJ47, P0DM41, P0DM42, P10981, P10984, P10986, P10990, P17304, P30162, P30163, P30167, P30171, P38673, P42023, P42025, P45885, P45886, P45889, P48465, P48975, P53455, P53456, P53457, P53458, P53470, P53471
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 157 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| COPI-independent Golgi-to-ER retrograde traffic | 17 | 33.3× | 2e-19 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 15 | 27.4× | 1e-15 |
| Aggrephagy | 10 | 23.4× | 5e-10 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 6 | 23.1× | 6e-06 |
| Formation of tubulin folding intermediates by CCT/TriC | 5 | 19.9× | 1e-04 |
| RHO GTPases activate IQGAPs | 6 | 19.6× | 2e-05 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 5 | 18.6× | 1e-04 |
| Loss of Nlp from mitotic centrosomes | 12 | 18.0× | 2e-10 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| positive regulation of microtubule polymerization | 6 | 30.9× | 2e-05 |
| mitotic spindle organization | 6 | 12.4× | 2e-03 |
| microtubule-based movement | 5 | 11.3× | 8e-03 |
| microtubule cytoskeleton organization | 11 | 10.2× | 1e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
39 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 2 |
| Likely pathogenic | 0 |
| Uncertain significance | 18 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (2)
| Variant ID | HGVS | Classification |
|---|---|---|
| 3342255 | Single allele | Pathogenic |
| 58780 | GRCh38/hg38 10q24.32-24.33(chr10:102243341-103929730)x1 | Pathogenic |
SpliceAI
3418 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 10:102469159:GT:G | donor_gain | 1.0000 |
| 10:102469992:GACA:G | acceptor_gain | 1.0000 |
| 10:102470094:GCTC:G | donor_gain | 1.0000 |
| 10:102470135:G:GT | donor_gain | 1.0000 |
| 10:102470972:G:GT | donor_gain | 1.0000 |
| 10:102471271:A:AG | acceptor_gain | 1.0000 |
| 10:102471272:G:GG | acceptor_gain | 1.0000 |
| 10:102472946:GTTGG:G | donor_gain | 1.0000 |
| 10:102472947:TTGGG:T | donor_loss | 1.0000 |
| 10:102472948:TGGGT:T | donor_loss | 1.0000 |
| 10:102472949:GG:G | donor_gain | 1.0000 |
| 10:102472949:GGGT:G | donor_loss | 1.0000 |
| 10:102472950:GG:G | donor_gain | 1.0000 |
| 10:102472950:GGT:G | donor_loss | 1.0000 |
| 10:102472952:TGAG:T | donor_loss | 1.0000 |
| 10:102472953:GAGT:G | donor_loss | 1.0000 |
| 10:102473565:CCCA:C | acceptor_loss | 1.0000 |
| 10:102473566:CCAGG:C | acceptor_loss | 1.0000 |
| 10:102473567:CAGG:C | acceptor_loss | 1.0000 |
| 10:102473568:A:AG | acceptor_gain | 1.0000 |
| 10:102473568:A:C | acceptor_loss | 1.0000 |
| 10:102473568:AG:A | acceptor_gain | 1.0000 |
| 10:102473569:G:GG | acceptor_gain | 1.0000 |
| 10:102473569:GG:G | acceptor_gain | 1.0000 |
| 10:102473569:GGC:G | acceptor_gain | 1.0000 |
| 10:102473569:GGCCT:G | acceptor_gain | 1.0000 |
| 10:102473739:CAGG:C | donor_loss | 1.0000 |
| 10:102473740:AGGTA:A | donor_loss | 1.0000 |
| 10:102473741:GGTA:G | donor_loss | 1.0000 |
| 10:102473742:G:C | donor_loss | 1.0000 |
AlphaMissense
2454 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 10:102480951:G:T | A348D | 1.000 |
| 10:102480963:C:T | G344D | 1.000 |
| 10:102480964:C:G | G344R | 1.000 |
| 10:102481132:C:A | G343V | 1.000 |
| 10:102481132:C:T | G343E | 1.000 |
| 10:102481133:C:A | G343W | 1.000 |
| 10:102481133:C:G | G343R | 1.000 |
| 10:102481133:C:T | G343R | 1.000 |
| 10:102481139:A:G | W341R | 1.000 |
| 10:102481139:A:T | W341R | 1.000 |
| 10:102482021:C:T | G302E | 1.000 |
| 10:102484335:C:T | G161E | 1.000 |
| 10:102484336:C:A | G161W | 1.000 |
| 10:102484353:C:T | G155E | 1.000 |
| 10:102484354:C:A | G155W | 1.000 |
| 10:102484354:C:G | G155R | 1.000 |
| 10:102484354:C:T | G155R | 1.000 |
| 10:102485723:A:G | L109P | 1.000 |
| 10:102488197:A:G | W90R | 1.000 |
| 10:102488197:A:T | W90R | 1.000 |
| 10:102490592:C:G | G24R | 1.000 |
| 10:102490612:C:T | G17E | 1.000 |
| 10:102502613:A:T | V12D | 1.000 |
| 10:102480925:A:G | W357R | 0.999 |
| 10:102480925:A:T | W357R | 0.999 |
| 10:102480935:A:C | F353L | 0.999 |
| 10:102480935:A:T | F353L | 0.999 |
| 10:102480937:A:G | F353L | 0.999 |
| 10:102480945:A:G | L350P | 0.999 |
| 10:102480952:C:G | A348P | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000011576 (10:102479760 A>C,G), RS1000108508 (10:102501291 A>G), RS1000179250 (10:102497795 AGAGAAAGGATAGGGTT>A), RS1000202518 (10:102483407 T>A,C), RS1000207326 (10:102491454 A>G), RS1000353249 (10:102494120 G>A), RS1000362988 (10:102479418 G>A,C,T), RS1000411697 (10:102503462 A>G), RS1000544013 (10:102496396 G>A), RS1000804231 (10:102485017 T>C), RS1000836347 (10:102482852 A>C), RS1000903610 (10:102492552 CTAAG>C), RS1000955573 (10:102492113 C>T), RS1001172987 (10:102489244 A>G), RS1001188825 (10:102480448 G>T)
Disease associations
OMIM: gene MIM:605143 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
13 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001942_1 | Prostate cancer | 5.000000e-10 |
| GCST004521_172 | Autism spectrum disorder or schizophrenia | 4.000000e-14 |
| GCST004521_53 | Autism spectrum disorder or schizophrenia | 9.000000e-10 |
| GCST005038_102 | Allergic disease (asthma, hay fever or eczema) | 2.000000e-08 |
| GCST005956_50 | Waist-to-hip ratio adjusted for BMI | 8.000000e-06 |
| GCST005958_15 | Waist-to-hip ratio adjusted for BMI (age >50) | 4.000000e-06 |
| GCST005962_36 | Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) | 6.000000e-07 |
| GCST006409_9 | Allergic rhinitis | 5.000000e-18 |
| GCST007387_8 | Insomnia symptoms (never/rarely vs. sometimes/usually) | 5.000000e-08 |
| GCST007388_47 | Insomnia symptoms (never/rarely vs. usually) | 4.000000e-11 |
| GCST010002_298 | Refractive error | 3.000000e-22 |
| GCST010703_271 | Brain morphology (MOSTest) | 5.000000e-13 |
| GCST012227_616 | Hip circumference adjusted for BMI | 4.000000e-11 |
EFO canonical traits (6, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0008007 | age at assessment |
| EFO:0008343 | sex interaction measurement |
| EFO:0007876 | insomnia measurement |
| EFO:0004346 | neuroimaging measurement |
| EFO:0008039 | BMI-adjusted hip circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
36 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, increases expression | 2 |
| Tobacco Smoke Pollution | affects expression, increases expression | 2 |
| bisphenol F | affects cotreatment, increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenite | increases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| diallyl trisulfide | increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| tanespimycin | affects cotreatment, decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| VER 155008 | affects cotreatment, decreases expression | 1 |
| LDN 193189 | increases expression, affects cotreatment | 1 |
| Atrazine | increases expression | 1 |
| Benztropine | affects cotreatment, increases expression | 1 |
| Cisplatin | increases expression | 1 |
| Cuprizone | affects cotreatment, increases expression | 1 |
| Dexamethasone | affects cotreatment, increases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Furaldehyde | affects cotreatment, affects localization, increases expression | 1 |
| Hydrogen Peroxide | increases expression | 1 |
| Indomethacin | increases expression, affects cotreatment | 1 |
| Ivermectin | decreases expression | 1 |
| Methotrexate | affects response to substance | 1 |
| Quercetin | increases expression | 1 |
| Selenium | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Sodium Chloride | affects cotreatment, affects localization, increases expression | 1 |
| T-2 Toxin | increases expression | 1 |
| Dronabinol | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): allergic rhinitis